PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 3, 2026BMJ Case Reports1 citations

Apixaban-induced anaphylaxis

View Full Paper
JPJessica Hyunji ParkJohns Hopkins UniversityBSBrett James SchuchardtJohns Hopkins UniversityCHChe Mathew HarrisJohns Hopkins University

Key Result

Apixaban ingestion caused a severe anaphylactic reaction, including dyspnoea, hypoxia, hypotension, and an urticarial rash, within an hour in a patient with deep vein thrombosis.

Key Points

  • To report a case of anaphylaxis induced by apixaban and highlight its importance as a rare side effect.
  • Case report of a patient with deep vein thrombosis treated with apixaban
  • Monitoring of symptoms after drug ingestion
  • Assessment of tryptase levels and clinical response to treatment
  • Patient experienced severe allergic reaction including dyspnoea and hypotension after taking apixaban
  • Elevated tryptase level confirmed anaphylactic reaction
  • Patient transitioned to enoxaparin and discharged the following day

Study Design

Type

Case Report (n=1)

Structured PICO

P
Population
1 female patient in her 60s presenting with left leg swelling and diagnosed with bilateral deep vein thrombosis.
I
Intervention
Apixaban (therapeutically indicated dose)
O
Outcome
Anaphylaxis (dyspnoea, hypoxia, hypotension, urticarial rash, and elevated tryptase level)safety

Apixaban can cause rare but potentially fatal anaphylaxis, highlighting the need for healthcare providers to recognize and promptly treat this adverse effect.

Abstract

Anaphylaxis is a rarely reported yet potentially fatal adverse effect of apixaban. This case involves a patient in her 60s who presented with left leg swelling and was diagnosed with bilateral deep vein thrombosis. Less than an hour after ingestion of therapeutically indicated apixaban, she experienced dyspnoea, hypoxia, hypotension and an urticarial rash. She was promptly treated with epinephrine, diphenhydramine and methylprednisolone and found to have an elevated tryptase level, a reliable marker for anaphylactic reactions. She clinically improved, transitioned to enoxaparin and was discharged the following day. This case encourages healthcare providers to consider anaphylaxis as a rare but potentially lethal side effect of apixaban.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Park et al. (2026) conducted a case report in Bilateral deep vein thrombosis (n=1). Apixaban was evaluated on Anaphylaxis. Apixaban ingestion caused a severe anaphylactic reaction, including dyspnoea, hypoxia, hypotension, and an urticarial rash, within an hour in a patient with deep vein thrombosis.

synapsesocial.com/papers/69cf5cd15a333a821460a641https://doi.org/10.1136/bcr-2026-272624
Ask AI
Helpful
Bookmark
Share
View Full Paper